MNG3
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.594
- IL6_JAK_STAT3_SIGNALING+0.550
- INFLAMMATORY_RESPONSE+0.477
- INTERFERON_GAMMA_RESPONSE+0.457
- KRAS_SIGNALING_UP+0.430
- TGF_BETA_SIGNALING+0.420
- ALLOGRAFT_REJECTION+0.390
- UV_RESPONSE_DN+0.319
- COMPLEMENT+0.310
- ANDROGEN_RESPONSE+0.295
Top 10 suppressed
- MYC_TARGETS_V2-0.484
- DNA_REPAIR-0.377
- OXIDATIVE_PHOSPHORYLATION-0.352
- MYC_TARGETS_V1-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.285
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.173
- ADIPOGENESIS-0.125
- MYOGENESIS-0.076
- PI3K_AKT_MTOR_SIGNALING-0.075
- GLYCOLYSIS-0.067
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9f621704-2ece-4b25-be28-5fe14f71048d | — | — | 0.872 |
| 2 | MDT-AP-2796 | Med | Medulloblastoma | 0.860 |
| 3 | MDT-AP-3277 | Med | Medulloblastoma | 0.852 |
| 4 | TCGA-E2-A1B1-01A-21R-A12P-07 | — | A | 0.852 |
| 5 | MDT-AP-2869 | Med | Medulloblastoma | 0.851 |
| 6 | BS_S4V9E1XJ | pilocytic astrocytoma | — | 0.846 |
| 7 | MDT-AP-3156 | Med | Medulloblastoma | 0.845 |
| 8 | BS_YY5B2XDD | pilocytic astrocytoma | — | 0.845 |
| 9 | TCGA-A8-A096-01A-11R-A00Z-07 | — | B | 0.841 |
| 10 | TCGA-D8-A27M-01A-11R-A16F-07 | — | D | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.594 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.550 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.477 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.457 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.430 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.319 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.295 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.279 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.216 | Inavolisib | — uncovered |
| HYPOXIA | 0.207 | Idelalisib | — uncovered |
| APOPTOSIS | 0.195 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.173 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.156 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.123 | Inavolisib | — uncovered |